Two promising heart drugs fail in major trials, dashing cardiologists' hopes
Two promising heart drugs fail in major trials, dashing cardiologists' hopes
Two promising heart drugs fail in major trials, dashing cardiologists' hopes
Key points
اہم نکات
मुख्य बातें
- Two heart drugs that cardiologists had high hopes for have both failed in large clinical trials, The New York Times reports.
- Novartis's pelacarsen cut levels of the fatty particle Lp(a) by about 80% in more than 8,300 patients, but it did not prevent heart attacks, strokes or heart-related deaths, with full results presented at the American Heart Association meeting in Chicago and published in the New England Journal of Medicine.
- Novo Nordisk's ziltivekimab also hit its target, lowering inflammation in 6,300 high-risk patients, yet failed to prevent major heart events.
- Two heart drugs that cardiologists had high hopes for have both failed in large clinical trials, The New York Times reports.
- Novartis's pelacarsen cut levels of the fatty particle Lp(a) by about 80% in more than 8,300 patients, but it did not prevent heart attacks, strokes or heart-related deaths, with full results presented at the American Heart Association meeting in Chicago and published in the New England Journal of Medicine.
- Novo Nordisk's ziltivekimab also hit its target, lowering inflammation in 6,300 high-risk patients, yet failed to prevent major heart events.
- Two heart drugs that cardiologists had high hopes for have both failed in large clinical trials, The New York Times reports.
- Novartis's pelacarsen cut levels of the fatty particle Lp(a) by about 80% in more than 8,300 patients, but it did not prevent heart attacks, strokes or heart-related deaths, with full results presented at the American Heart Association meeting in Chicago and published in the New England Journal of Medicine.
- Novo Nordisk's ziltivekimab also hit its target, lowering inflammation in 6,300 high-risk patients, yet failed to prevent major heart events.
Two heart drugs that cardiologists had high hopes for have both failed in large clinical trials, The New York Times reports. Novartis's pelacarsen cut levels of the fatty particle Lp(a) by about 80% in more than 8,300 patients, but it did not prevent heart attacks, strokes or heart-related deaths, with full results presented at the American Heart Association meeting in Chicago and published in the New England Journal of Medicine. Novo Nordisk's ziltivekimab also hit its target, lowering inflammation in 6,300 high-risk patients, yet failed to prevent major heart events. Experts called the double setback a huge blow, though other Lp(a) drugs from Amgen and Eli Lilly are still in trials.
Two heart drugs that cardiologists had high hopes for have both failed in large clinical trials, The New York Times reports. Novartis's pelacarsen cut levels of the fatty particle Lp(a) by about 80% in more than 8,300 patients, but it did not prevent heart attacks, strokes or heart-related deaths, with full results presented at the American Heart Association meeting in Chicago and published in the New England Journal of Medicine. Novo Nordisk's ziltivekimab also hit its target, lowering inflammation in 6,300 high-risk patients, yet failed to prevent major heart events. Experts called the double setback a huge blow, though other Lp(a) drugs from Amgen and Eli Lilly are still in trials.
Two heart drugs that cardiologists had high hopes for have both failed in large clinical trials, The New York Times reports. Novartis's pelacarsen cut levels of the fatty particle Lp(a) by about 80% in more than 8,300 patients, but it did not prevent heart attacks, strokes or heart-related deaths, with full results presented at the American Heart Association meeting in Chicago and published in the New England Journal of Medicine. Novo Nordisk's ziltivekimab also hit its target, lowering inflammation in 6,300 high-risk patients, yet failed to prevent major heart events. Experts called the double setback a huge blow, though other Lp(a) drugs from Amgen and Eli Lilly are still in trials.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।